SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Enters Technology Transfer Agreement with Intravacc to Develop and Commercialize Sabin Inactivated Polio Vaccine (sIPV) -- Collaborating with World Health Organization and Intravacc to Develop sIPV in line with mission to secure a lasting polio-free world, free of all paralytic polio disease Sinovac Enters Technology Transfer Agreement with Intravacc to Develop and Commercialize Sabin Inactivated Polio Vaccine (sIPV) Collaborating] [Sinovac to Host Conference Call to Report First Quarter 2014 Unaudited Financial Results BEIJING, May 12, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the first quarter ended March 31, 2014, after market closes on Wednesday, May 21, 2014 EDT. The Company] [Sinovac Reports Unaudited First Quarter 2014 Financial Results -- -Conference call scheduled for Thursday, May 22, 2014 at 8:00 AM EDT Sinovac Reports Unaudited First Quarter 2014 Financial Results - Conference call scheduled for Thursday, May 22, 2014 at 8:00 AM EDT - BEIJING, May 21, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products] []

By | 2016-03-16T07:14:15+00:00 June 24th, 2014|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments
Read More

SVA [SINOVAC BIOTECH] 6-K: Sinovac Enters Technology Transfer Agreement with Intravacc to

[Sinovac Enters Technology Transfer Agreement with Intravacc to Develop and Commercialize Sabin Inactivated Polio Vaccine (sIPV) -- Collaborating with World Health Organization and Intravacc to Develop sIPV in line with mission to secure a lasting polio-free world, free of all paralytic polio disease Sinovac Enters Technology Transfer Agreement with Intravacc to Develop and Commercialize Sabin Inactivated Polio Vaccine (sIPV) Collaborating] [Sinovac to Host Conference Call to Report First Quarter 2014 Unaudited Financial Results BEIJING, May 12, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the first quarter ended March 31, 2014, after market closes on Wednesday, May 21, 2014 EDT. The Company] [Sinovac Reports Unaudited First Quarter 2014 Financial Results -- -Conference call scheduled for Thursday, May 22, 2014 at 8:00 AM EDT Sinovac Reports Unaudited First Quarter 2014 Financial Results - Conference call scheduled for Thursday, May 22, 2014 at 8:00 AM EDT - BEIJING, May 21, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products] []

By | 2016-03-16T07:16:16+00:00 June 24th, 2014|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments
Read More

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Files 2013 Annual Report on Form 20-F The Company will provide a hard copy of its complete audited financial statements to its shareholders upon request, free of charge. Requests for a hard copy of the 2013 Annual Report can be made through the Contact IR page in the Investor Relations section of the Company's website by submitting complete mailing] [Sinovac Receives Notification of China Government Grant for EV71 Vaccine Project -- RMB 60 Million Free Grant for Construction of Dedicated Production Facility SVA BEIJING, April 24, 2014 -- Sinovac Biotech Ltd. (NASDAQ: Enterovirus 71 (EV71) vaccine against hand foot and mouth disease (HFMD). Given the severity of HFMD epidemic levels in China and the government’s focus on developing the] []

By | 2016-03-16T07:17:44+00:00 April 28th, 2014|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments
Read More

SVA [SINOVAC BIOTECH] 6-K: Sinovac Files 2013 Annual Report on Form 20-F

[Sinovac Files 2013 Annual Report on Form 20-F The Company will provide a hard copy of its complete audited financial statements to its shareholders upon request, free of charge. Requests for a hard copy of the 2013 Annual Report can be made through the Contact IR page in the Investor Relations section of the Company's website by submitting complete mailing] [Sinovac Receives Notification of China Government Grant for EV71 Vaccine Project -- RMB 60 Million Free Grant for Construction of Dedicated Production Facility SVA BEIJING, April 24, 2014 -- Sinovac Biotech Ltd. (NASDAQ: Enterovirus 71 (EV71) vaccine against hand foot and mouth disease (HFMD). Given the severity of HFMD epidemic levels in China and the government’s focus on developing the] []

By | 2016-03-16T07:18:40+00:00 April 28th, 2014|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments
Read More

SVA [SINOVAC BIOTECH] 20-F: (Original Filing)

[None (Title of Class) Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report. 55,570,361 common shares as of December 31, 2013 o Yes x No o Yes x No x Yes o No x Yes o No Large accelerated filer] [4.20 April 1 6 , 2014 100 F Street, N.T. Ladies and Gentlemen: We have read Item 16F of the Annual Report on Form 20-F for the year ended December 31, 2013 dated April 1 6 Vancouver, Canada EX-4.20 2 a14-4385_1ex4d20.htm EX-4.20] [List of Subsidiaries 1. Sinovac Biotech (Hong Kong) Ltd., a Hong Kong company 2. Tangshan Yian Biological Engineering Co., Ltd., a PRC company 3. Sinovac Biotech Co., Ltd., a PRC company 4. Sinovac Research and Development Co., Ltd. (formerly known as Beijing Sinovac Biological Technology Co., Ltd.), a PRC company 5. Sinovac (Dalian) Vaccine Technology Co., Ltd., a PRC company] [Certification by the Chief Executive Officer I, Weidong Yin, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (t he “ Company ”) ; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements] [Certification by the Chief Financial Officer I, Nan Wang, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. ( the “ Company ”) ; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements] [Certification by the Chief Executive Officer In connection with the annual report of Sinovac Biotech Ltd. Weidong Yin (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. 16 , 2014 Weidong Yin Chief Executive Officer 1 EX-13.1 6 a14-4385_1ex13d1.htm EX-13.1] [Certification by the Chief Financial Officer In connection with the annual report of Sinovac Biotech Ltd. (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. 16 , 2014 Nan Wang Chief Financial Officer 1 EX-13.2 7 a14-4385_1ex13d2.htm EX-13.2] [Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement on Form S-8 (No.333-161827) pertaining to Sinovac Biotech Ltd.’s 2003 Stock Option Plan and the Registration Statement on Form S-8 (No.333-190980) pertaining to Sinovac Biotech Ltd.’s 2012 Share Incentive Plan of our reports dated April 16, 2014, with respect to the consolidated] [Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement onForm S-8 (No. 333-161827) pertaining Sinovac Biotech Ltd.’s 2003 Stock Option Plan and the Registration Statement on Form S-8 (No. 333-190980) pertaining to Sinovac Biotech Ltd.’s 2012 Share Incentive Plan of our report dated April 29, 2013, with respect to the consolidated]

By | 2016-03-16T07:22:55+00:00 April 16th, 2014|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments
Read More

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Files Clinical Trial Application with CFDA for its Proprietary Vaccine — -Preclinical development completed for H7N9 vaccine candidates that addresses significant BEIJING, January 29, 2014—Sinovac Biotech Ltd. (Nasdaq:SVA), a leading provider of biopharmaceutical products in China, announced today that it has submitted a Clinical Trial Application(CTA) with the China Food and Drug Administration(CFDA) to commence human clinical trials for] [Sinovac’s EV71 Vaccine Phase III Clinical Trial Results Published in New — Study shows vaccine provides protection against EV71-associated hand, foot and mouth th The New England Journal of Medicine BEIJING, Feb. 26, 2014 /PRNewswire/ — Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that Phase III clinical trial results for its proprietary] [Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2013 BEIJING, March 12, 2014 — Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the fourth quarter and whole year ended December 31, 2013, after market closes on Wednesday, March 19, 2014] [Sinovac Reports Unaudited Fourth Quarter and Full Year 2013 Financial Results - Conference call scheduled for Thursday, March 20, 2014 at 8:00 AM EDT - BEIJING, March 19, 2014 /PRNewswire/ — Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited fourth quarter and full year financial results for the period ended December] []

By | 2016-03-16T07:25:26+00:00 March 24th, 2014|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments
Read More

SVA [SINOVAC BIOTECH] 6-K: Sinovac Files Clinical Trial Application with CFDA for

[Sinovac Files Clinical Trial Application with CFDA for its Proprietary Vaccine — -Preclinical development completed for H7N9 vaccine candidates that addresses significant BEIJING, January 29, 2014—Sinovac Biotech Ltd. (Nasdaq:SVA), a leading provider of biopharmaceutical products in China, announced today that it has submitted a Clinical Trial Application(CTA) with the China Food and Drug Administration(CFDA) to commence human clinical trials for] [Sinovac’s EV71 Vaccine Phase III Clinical Trial Results Published in New — Study shows vaccine provides protection against EV71-associated hand, foot and mouth th The New England Journal of Medicine BEIJING, Feb. 26, 2014 /PRNewswire/ — Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that Phase III clinical trial results for its proprietary] [Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2013 BEIJING, March 12, 2014 — Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the fourth quarter and whole year ended December 31, 2013, after market closes on Wednesday, March 19, 2014] [Sinovac Reports Unaudited Fourth Quarter and Full Year 2013 Financial Results - Conference call scheduled for Thursday, March 20, 2014 at 8:00 AM EDT - BEIJING, March 19, 2014 /PRNewswire/ — Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited fourth quarter and full year financial results for the period ended December] []

By | 2016-03-16T07:26:42+00:00 March 24th, 2014|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments
Read More

SVA [SINOVAC BIOTECH] SC 13D/A: (Original Filing)

[13D CUSIP No. P8696W104 Page 2 1. Names of Reporting Persons. S.S. or I.R.S. Identification Nos. of Above Persons John M. Gregory 2. Check the Appropriate Box if a Member of a Group (See Instructions) ¨ x (a) 3. SEC Use Only 4. Source of Funds (See Instructions) OO 5. 6. Citizenship or Place of Organization]

By | 2016-03-16T09:05:47+00:00 March 5th, 2014|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments
Read More

SVA [SINOVAC BIOTECH] SC 13D/A: 13D CUSIP No. P8696W104 Page 2 1. Names

[13D CUSIP No. P8696W104 Page 2 1. Names of Reporting Persons. S.S. or I.R.S. Identification Nos. of Above Persons John M. Gregory 2. Check the Appropriate Box if a Member of a Group (See Instructions) ¨ x (a) 3. SEC Use Only 4. Source of Funds (See Instructions) OO 5. 6. Citizenship or Place of Organization]

By | 2016-03-16T09:07:12+00:00 March 5th, 2014|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments
Read More

SVA [SINOVAC BIOTECH] SC 13G: (Original Filing)

[(Name of Issuer) Common Stock (Title of Class of Securities) P8696W104 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * CUSIP No. P8696W104 1. NAMES OF REPORTING PERSONS 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 3. SEC USE ONLY]

By | 2016-03-16T09:09:54+00:00 February 14th, 2014|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments
Read More
Skip to toolbar